Amylase: A Comprehensive Reference
1. Identity: Names, Classification, and Sources
1.1 Chemical and Taxonomic Identity
Amylase is any member of a class of enzymes that catalyze the hydrolysis (splitting of a compound by addition of a water molecule) of starch into smaller carbohydrate molecules such as maltose (a molecule composed of two glucose molecules). In formal enzyme nomenclature, the primary human-relevant form is classified under Enzyme Commission number EC 3.2.1.1, and belongs to glycoside hydrolase family 13 (GH13).
Amylase is a digestive enzyme predominantly secreted by the pancreas and salivary glands, with minimal presence in other tissues. The enzyme was first described in the early 1800s and is considered one of the earliest subjects of enzymology. Initially termed diastase, the enzyme was renamed amylase in the early 20th century.
Specifically, humans produce a version called alpha-amylase, also historically known as ptyalin. Three categories of amylases, denoted alpha, beta, and gamma, differ in the way they attack the bonds of the starch molecules.
- Alpha-amylase (α-amylase; EC 3.2.1.1): α-Amylases are found in humans, animals, plants, as well as in microbes. They are calcium metalloenzymes that cleave random α-1,4 glycosidic bonds to yield either maltose and maltotriose from amylose chains or glucose, maltose and dextrin from amylopectin chains.
- Beta-amylase (β-amylase): β-Amylase is a calcium-independent enzyme that catalyzes the hydrolysis of α-1,4-glycosidic linkages at the nonreducing end of starch molecules, yielding a maltose unit. Beta-amylases are present in yeasts, molds, bacteria, and plants, particularly in the seeds. They are the principal components of a mixture called diastase that is used in the removal of starchy sizing agents from textiles and in the conversion of cereal grains to fermentable sugars. Beta-amylase has an optimum pH of 4.0–5.0.
- Gamma-amylase (γ-amylase): γ-Amylase catalyzes the hydrolysis of the last α-1,4-glycosidic bond at the nonreducing end of starch yielding one glucose unit; γ-amylase is mostly active in acidic conditions.
The optimum pH of alpha-amylase, the primary form used in human supplements, is 6.7–7.0.
1.2 Natural Sources
Alpha-amylase (α-Amylase) is the major form of amylase found in humans and other mammals and is mainly made by the pancreas and salivary glands, but it is also produced by the small intestine mucosa, ovaries, placenta, liver, and fallopian tubes.
Beyond human physiology, amylase is present across a broad range of organisms. Amylase is naturally sourced from human saliva and pancreas, porcine/bovine pancreas (historical), plants (barley), and extensively from microbial fermentation (Bacillus, Aspergillus). For commercial and supplement production purposes, microorganisms such as Aspergillus oryzae, A. niger, Bacillus amyloliquefaciens, B. circulans, and B. licheniformis are involved in alpha-amylase production.
Aspergillus oryzae, which is one of the most potent secretory producers of proteins among filamentous fungi, has been used for hundreds of years in Japanese traditional fermentation industries including oriental alcoholic beverages such as sake (rice wine) and shochu (spirits), miso (soybean paste), and shoyu (soy sauce). The patented production of A. oryzae Taka-diastase, a neutral α-amylase, as a medicine in 1894 marked the beginning of modern enzyme biotechnology.
1.3 Common Forms and Preparations
Commercial enzyme preparations are produced by controlled fermentation, purification, activity standardization, and formulated as powders, enteric beads, capsules, or chewables. A key distinction in how amylase supplements are measured: typical over-the-counter formulations are measured in enzymatic activity units (commonly thousands to tens of thousands of units per serving) rather than milligrams; enteric-coated beads retain more than 50% activity to the duodenum in many validated products.
Amylase is also a component of prescription pancreatic enzyme replacement therapies. Pancrelipase is a combination of lipase, protease, and amylase enzymes used to treat exocrine pancreatic insufficiency due to cystic fibrosis and other gastrointestinal disorders.
For regulatory context in the United States, Aspergillus oryzae is Generally Recognized as Safe (GRAS) by the US Food and Drug Administration (FDA), meeting the safety needs of industrial production. Separately, A. oryzae has been approved as a safe microorganism by the World Health Organisation (WHO).
2. Historical and Traditional Use
2.1 Earliest Scientific Discovery
In 1831, Erhard Leuchs reported that starch is broken down when mixed with human saliva and used the name ptyalin to describe the agent in saliva that was responsible for the chemical reaction. This seems to have been one of the earliest accounts of an enzyme experiment and soon after, in 1833, Payen and Persoz isolated an enzyme from barley that broke down starch and named it diastase. It is from this term that all subsequent enzyme names tend to end in the suffix -ase.
In 1862, Russian biochemist Aleksandr Yakovlevich Danilevsky (1838–1923) separated pancreatic amylase from trypsin. By 1878–1900, biochemical separation and clinical recognition that saliva and pancreas secrete starch-digesting activity occurred, along with early use of serum amylase as a pancreatitis biomarker. In the 1950s–1970s, enzymology matured and X-ray crystallography provided structural insights into active-site residues. In the 1990s–2000s, recombinant and microbial production scaled industrial and supplement use, and salivary amylase gained traction as a stress biomarker.
2.2 Traditional Cultural Uses
The use of amylase in its natural, food-based context has deep cross-cultural roots. In some historic methods of producing alcoholic beverages, the conversion of starch to sugar starts with the brewer chewing grain to mix it with saliva. This practice continues to be practiced in home production of some traditional drinks, such as chhaang in the Himalayas, chicha in the Andes, and kasiri in Brazil and Suriname. In these traditions, the salivary amylase delivered by chewing acted as the essential saccharification agent, converting grain starches to fermentable sugars.
Amylases are used in breadmaking and to break down complex sugars, such as starch (found in flour), into simple sugars. Yeast then feeds on these simple sugars and converts them into the waste products of ethanol and carbon dioxide, which imparts flavor and causes the bread to rise.
Traditional medicinal use is limited; crude enzyme-rich preparations were used in some traditional practices to aid digestion of starchy foods. Historically, amylase was used in malt for brewing and bread, and modern use includes industrial starch processing, detergents, and nutraceutical digestive enzyme products, plus clinical measurement for pancreatic disease.
2.3 Evolutionary Context
Many mammals have seen great expansions in the copy number of the amylase gene. These duplications allow for the pancreatic amylase AMY2 to re-target to the salivary glands, allowing animals to detect starch by taste and to digest starch more efficiently and in higher quantities. This has happened independently in mice, rats, dogs, pigs, and most importantly, humans after the agricultural revolution. Humans have significantly more copies of the AMY1 gene (which codes for salivary amylase) than our primate cousins like chimpanzees. This suggests that as our ancestors moved toward diets higher in cooked starches and tubers, our bodies adapted by producing more "spit power" to handle the load.
3. Key Constituents and Active Compounds
3.1 Protein Structure
Human pancreatic alpha-amylase has been extensively characterized at the structural level. The structure of human pancreatic alpha-amylase has been determined to 1.8 Å resolution using X-ray diffraction techniques. This enzyme is found to be composed of three structural domains. The largest is Domain A (residues 1–99, 169–404), which forms a central eight-stranded parallel beta-barrel, to one end of which are located the active site residues Asp 197, Glu 233, and Asp 300. Domain B is the smallest (residues 100–168) and serves to form a calcium binding site against the wall of the beta-barrel of Domain A. Protein groups making ligand interactions to this calcium include Asn 100, Arg 158, Asp 167, and His 201.
Throughout the alpha-amylase family, only eight amino acid residues are invariant, seven at the active site and a glycine in a short turn.
3.2 Role of Calcium and Chloride
Amylase requires calcium ions for enzymatic activity. Functional integrity of amylase depends on the presence of calcium. Full enzymatic activity requires specific anions, including chloride, bromide, nitrate, or monohydrogen phosphate, with chloride and bromide serving as the most effective activators. The "essential" calcium ion has been located near the active site region and between two domains, each of them providing two calcium ligands. On the basis of sequence comparisons, this calcium binding site is suggested to be a common structural feature of all alpha-amylases.
3.3 Genetic Encoding: The AMY1 and AMY2 Genes
Amylase in humans is encoded by two principal gene families. The human salivary amylase genes display extensive copy number variation (CNV), and recent work has implicated this variation in adaptation to starch-rich diets, and in association with body mass index. The human amylase gene cluster is a highly repetitive, copy number-variable region that has undergone expansion in gene number specifically in the human lineage. AMY1 copy number correlates with salivary amylase concentration in saliva.
The relationship between AMY1 copy number and disease susceptibility is an active research area. Salivary amylase initiates the digestion of starch and it has been hypothesized that salivary amylase may play a role in the development of insulin resistance and type 2 diabetes. A large epidemiological study examined this hypothesis in detail.
4. Mechanisms of Action
4.1 Primary Digestive Action
The primary function of amylases is to hydrolyze glycosidic bonds in starch molecules, converting complex carbohydrates into simpler sugars. More specifically, it digests carbohydrates (polysaccharides) into smaller disaccharide units, eventually converting them into monosaccharides, such as glucose.
The amylase secreted by the salivary glands kicks off the enzymatic digestion of starches in the mouth as food is chewed and mixed with saliva. This step in starch digestion continues in the first section of the small intestine (the duodenum), the region into which pancreatic juices empty. The by-products of amylase hydrolysis are ultimately broken down by other enzymes into molecules of glucose, which are rapidly absorbed through the intestinal wall.
4.2 Supplemental Amylase: Luminal Augmentation
When amylase is administered as a dietary supplement, its proposed mechanism relies on augmenting the luminal pool of the enzyme. Supplemental amylase increases luminal enzymatic capacity to cleave α-1,4 bonds, producing absorbable oligosaccharides. The enzyme amylase helps to relieve the burden of digestion on the small intestine by breaking down food particles while still in the mouth. If this important enzyme were not excreted in the saliva, the small intestine would have a much harder time breaking down sugars and starches. In this way, amylase helps the entire functioning of the digestive system.
4.3 Intestinal Mucosal Effects
Research in animal models has begun to reveal roles for amylase beyond simple luminal carbohydrate hydrolysis. A 2025 porcine study examined the impact of microbial-derived alpha-amylase (MD amylase) on small intestinal structure in surgically induced exocrine pancreatic insufficiency. EPI led to reduced villus length, crypt depth, and thickness of the mucosa and muscularis layers compared to those of healthy pigs. All these changes appeared to be reversible after enzyme supplementation. Brush border thickness was decreased in EPI and increased with both enzyme preparations, with MD amylase treatment leading to the highest values in the proximal jejunum. No EPI-induced changes were observed in the goblet cell (GC) population, but significant increases in GC number and area were observed following MD amylase treatment. Both orally administered MD amylase and a mixture of porcine pancreatic enzymes were able to recover the structure of intestinal segments. The fact that isolated MD amylase was as efficacious as the mixture of lipase, protease, and amylase that is pancrelipase indicates that amylase may have independent structural effects on the intestinal wall. These findings are animal-model data and have not yet been replicated in human clinical trials.
5. Scientific Evidence by Area of Use
5.1 Exocrine Pancreatic Insufficiency (EPI) and Enzyme Replacement
The strongest clinical evidence for amylase use is in the context of exocrine pancreatic insufficiency, where amylase is a component of prescription enzyme replacement therapy (ERT), most commonly as part of pancrelipase. The required daily dose of pancreatin is variable, being related to the etiology and severity of pancreatic insufficiency and clinical features of the patient, such as age and body weight, and, for cystic fibrosis, also genotype and intestinal factors affecting absorption. Preparations of pancreatic enzyme are dosed by lipase content.
Liprotamase is a novel biotechnology-derived, non-porcine enzyme replacement therapy containing three purified and stable enzymes: cross-linked crystalline lipase, crystalline protease, and amorphous amylase. Since the stability (resistance against proteolysis and stability at acid pH) is an intrinsic characteristic of the individual enzyme, coating is not required. In a phase III trial, a dose of one capsule per meal (5 capsules per day) was well tolerated, increased fat and protein absorption, and significantly decreased stool weight in patients with cystic fibrosis.
Evidence strength: For EPI treatment in cystic fibrosis and chronic pancreatitis, amylase as part of pancrelipase/pancreatin formulations is supported by phase III clinical trial data and is FDA-approved. However, amylase is not the dose-limiting or primary active component in these preparations; clinical dosing is driven by lipase content.
5.2 Functional Dyspepsia and General Digestive Symptoms
Several clinical trials have examined multi-enzyme supplements containing amylase for functional dyspepsia (FD) — a condition characterized by bloating, fullness, belching, and postprandial distress. Digestive enzymes, such as amylase, protease, and lipase are produced and secreted by the GI system. Deficiency in digestive enzymes is also believed to be one of the contributing factors for FD, although the possible role of enzyme deficiency in its etiopathogenesis remains unclear.
A randomized, double-blind, placebo-controlled, parallel-group study evaluated DigeZyme®, a proprietary five-enzyme complex containing alpha-amylase. Safety and efficacy of DigeZyme®, a proprietary multienzyme complex (MEC), was evaluated as a dietary supplement in FD patients. In this randomized, double-blind, placebo-controlled, parallel-group study, 40 patients were randomly assigned (1:1 ratio) to receive either MEC (50 mg, TID; n = 20) or placebo (n = 20) for 60 days. Supplementation of DigeZyme® for 60 days showed significant improvement in efficacy parameters and reduction in gastric and intestinal symptoms.
A separate monocentric randomized double-blind placebo-controlled clinical trial examined a broad-spectrum enzyme blend. Each vegetable capsule of Poolzyme® Multi supplement contains 200 mg of a broad-spectrum digestive enzyme blend (i.e., protease, amylase, lipase, cellulase, and lactase). Placebo in the same format consisted of capsules containing inert excipients. A monocentric, randomized, placebo-controlled, parallel-group, double-blind clinical trial was performed to evaluate the effects of the target commercial food supplement based on a multi-enzyme blend in generally healthy adults with functional dyspepsia.
In a double-blind, crossover study, a combination of digestive enzymes, such as lipase, protease, and amylase, reduced the postprandial symptoms, such as bloating, gas, and fullness after ingestion of a high-calorie, high-fat meal in healthy volunteers.
Evidence strength: The evidence for multi-enzyme supplements containing amylase in functional dyspepsia is preliminary and limited. Most trials are small (n=40 or fewer), of short duration (up to 60 days), and test combination products rather than amylase in isolation. It is therefore not possible to attribute observed effects specifically to amylase rather than to co-administered enzymes such as lipase and protease. Larger, amylase-specific trials are lacking.
5.3 In Vitro Digestion Modeling
A 2024 PMC-indexed study used laboratory digestion models to explore the effect of a multi-enzyme supplement containing amylase on complex food. The effect of digestive enzyme supplement (DigeSEB Super containing amylase 20,000 SKBU/g, protease 13,000 PC/g, lipase 5 LU/g, cellulase 1000 CMC/g, lactase 1000 ALU/g, and hemicellulase 15,000 XU/g) on complex food digestion was assessed using INFOGEST simulated static digestion model and modified semi-dynamic digestion model. The progress of digestion was monitored in terms of reducing sugars, free sugar profile, degree of hydrolysis, free amino acids, peptide pattern, and free fatty acids.
Evidence strength: In vitro digestion modeling confirms the expected enzymatic activity of amylase-containing supplements under simulated digestive conditions but does not constitute clinical efficacy evidence in humans.
5.4 Macronutrient Absorption in Ileostomy Subjects
A randomized, double-blinded, placebo-controlled exploratory study assessed the Elevase® enzyme blend (which included amylase among multiple other enzymes) in individuals who had undergone an ileostomy. The post-hoc analyses on the placebo and Elevase® arms were specifically aimed to assess the efficacy of Elevase® in metabolizing carbohydrate, lipid, and proteins in the ileal effluent when co-administered with a meal. The reason for this could be the fact that amylose was broken down by the action of salivary and pancreatic amylases and Elevase® into glucose and maltose.
Evidence strength: This study provides mechanistic evidence in a controlled human model that amylase-containing preparations increase carbohydrate breakdown in vivo. However, the enzyme blend used contains many enzymes beyond amylase, limiting attribution of effects to any single component.
5.5 AMY1 Gene Copy Number, Obesity, and Metabolic Outcomes
A growing body of research has investigated the relationship between AMY1 gene copy number (and thus endogenous salivary amylase production) and metabolic health outcomes. A study of 3,624 adults without diabetes or elevated blood glucose in the Malmö Diet Cancer cohort assessed the associations and interactions between starch intake, AMY1 copies, and glucose homeostasis traits (i.e., fasting plasma glucose, insulin, and HOMA-IR) and risk of type 2 diabetes over an average of 18 follow-up years. AMY1 copy number was not associated with glucose, insulin, or HOMA-IR. A significant interaction between starch intake and AMY1 copies on insulin and HOMA-IR was observed after adjusting for potential confounders (p < 0.05).
Evidence strength: This is observational, epidemiological evidence. It suggests a gene-diet interaction whereby the amount of amylase produced (related to AMY1 copy number) may modulate the metabolic response to dietary starch, but does not prove that exogenous amylase supplementation would produce equivalent effects. Research in this domain remains active and findings have been inconsistent across studies.
5.6 Serum Amylase as a Diagnostic Biomarker
A distinct but important scientific use of amylase knowledge is in clinical diagnostics. Amylase levels exceeding 3 times the upper reference limit strongly suggest acute pancreatitis. Most patients will have elevations in serum levels of amylase or lipase within a few hours of the onset of symptoms. Lipase tends to remain elevated longer than amylase. Amylase and lipase levels above three times the upper limit of normal are mostly associated with pancreatitis.
For chronic pancreatitis, significant and independent associations between plasma amylase level and duration of chronic pancreatitis as well as the presence of exocrine pancreatic insufficiency and diabetes were observed (all p < 0.001). An amylase level below 17.3 U/l had a high specificity (94%) and moderate sensitivity (59%) for the diagnosis of chronic pancreatitis.
However, serum amylase is not pathognomonic for pancreatitis. Physiological phenomena, multiple diverse intra- and extra-abdominal pathologies, and pharmaceutical agents can all raise pancreatic enzyme levels, potentially leading to false positives when evaluating for acute pancreatitis. Conversely, conditions such as exocrine pancreatic insufficiency (e.g., chronic alcohol abuse) and hypertriglyceridemia, along with the timing of enzyme sampling (very early or late presentations), can reduce the sensitivity of these markers for acute pancreatitis.
6. Body Systems and Health Areas of Association
6.1 Gastrointestinal System
Amylase is a central player in the gastrointestinal tract. Amylase, protease, and lipase are the three main and most vital digestive enzymes the body utilizes to digest food. Digestive enzymes, such as amylase, protease, and lipase, are produced and secreted by the GI system and aid in digestion by facilitating the breakdown of larger molecules present in food, such as carbohydrates, proteins, and fats, respectively, followed by absorption of nutrients. Disruption of pancreatic amylase secretion, as occurs in chronic pancreatitis and cystic fibrosis, results in maldigestion of dietary carbohydrates and broader nutritional consequences.
6.2 Pancreatic Health
The pancreas is the primary organ of amylase biosynthesis for post-oral digestion. Measurement of serum and urinary amylase is a cornerstone of pancreatic disease assessment. Amylases are used clinically as biomarkers (serum amylase for pancreatitis). Reduced pancreatic amylase output is a consequence and indicator of chronic pancreatitis and exocrine pancreatic insufficiency.
6.3 Metabolic and Glycemic Regulation
Salivary amylase initiates the digestion of starch and it has been hypothesized that salivary amylase may play a role in the development of insulin resistance and type 2 diabetes. The association between AMY1 copy number (reflecting endogenous salivary amylase levels) and obesity risk has been investigated, with some studies reporting inverse associations between low copy number and higher BMI, though results remain mixed across population studies.
6.4 Oral and Salivary Function
The copy number variant AMY1 encodes the salivary amylase enzyme which promotes starch digestion. Although this gene has been associated with dental caries and periodontal disease susceptibility, the impact of the interaction between AMY1 CN and starch on oral biofilms is unclear. Salivary amylase plays a role in oral starch clearance and may influence the composition of the oral microbiome, with potential downstream effects on oral health.
7. Dosage Forms and Doses Reported in Studies
Amylase supplements are measured primarily in enzyme activity units rather than gravimetric mass, as activity (not mass) determines biological potency. The following doses have been reported in studies and formulations referenced in the peer-reviewed and patent literature:
- DigeZyme® (multienzyme complex including alpha-amylase): 50 mg, three times daily (TID), for 60 days, in a randomized controlled trial in functional dyspepsia patients (n=40).
- DigeSEB Super (amylase component): Amylase at 20,000 SKBU/g in an in vitro study of complex food digestion.
- Poolzyme® Multi (multienzyme blend including amylase): 200 mg of a broad-spectrum digestive enzyme blend per vegetable capsule in a randomized double-blind controlled clinical trial.
- Pancrelipase/Liprotamase (amylase as component): A dose of one capsule per meal (5 capsules per day) was well tolerated in a phase III trial in patients with cystic fibrosis. Preparations of pancreatic enzyme are dosed by lipase content rather than amylase content.
- General OTC supplement range: Typical amylase supplement doses range from 1,000 to 50,000 enzymatic activity units per serving.
Dose standardization across studies is poor, as different units of measure (SKB units, DU, CU, SKBU) are used by different manufacturers, and no universal standard for supplemental amylase dosing in healthy adults has been established by regulatory or scientific bodies.
8. Safety Considerations and Interactions
8.1 General Tolerability
DigeZyme® has self-affirmed Generally Recognized As Safe status in the United States. Aspergillus oryzae, the primary microbial source of supplement-grade amylase, is listed as "Generally Recognized as Safe" (GRAS) by the FDA and has been approved as a safe microorganism by the World Health Organisation (WHO).
8.2 Oral and Mucosal Considerations
A safety concern specific to high-dose enzyme preparations is delivery method. Crushing or chewing the pancrelipase formulation can cause it to release enzymes in the oral cavity, leading to mucosal irritation or stomatitis. This consideration applies specifically to enteric-coated pancreatic enzyme replacement products and is less relevant for standard OTC supplement capsules dosed at lower activity levels.
8.3 Antacid Interactions
The efficacy of gastrointestinal enzyme replacement therapy is reduced by antacids. This is a clinically documented interaction for pancrelipase-grade enzyme products; the potential significance for lower-activity OTC supplements has not been studied.
8.4 Rare Hematological Effects
Pancrelipase is commonly administered to patients with chronic pancreatitis and has rarely been associated with drug-induced neutropenia. While transient neutropenia was reported in a cystic fibrosis study, a case represents possible pancrelipase-induced neutropenia; however, additional research is required. This effect has been noted only in the context of high-dose prescription-grade pancreatic enzyme replacement therapy, not OTC digestive enzyme supplements.
8.5 Serum Amylase Elevation and Pancreatitis Monitoring
Elevated serum amylase is an important clinical signal. Amylase and lipase levels above three times the upper limit of normal are mostly associated with pancreatitis. Physiological phenomena, multiple diverse intra- and extra-abdominal pathologies, and pharmaceutical agents can all raise pancreatic enzyme levels, potentially leading to false positives when evaluating for acute pancreatitis. This means that the serum amylase test, while useful, requires careful clinical interpretation.
8.6 Limitations of the Evidence Base
It bears noting that the safety profile of amylase as an isolated OTC supplement ingredient has not been systematically studied in long-term human trials. Most safety data derive from combination enzyme products (pancrelipase, multienzyme complexes), from animal studies, or from in vitro experiments. Clinical studies demonstrating the safety and therapeutic benefits of digestive enzyme complex supplementation in FD patients are not adequate. The field lacks large randomized controlled trials evaluating amylase supplementation in isolation over extended periods.
References
Go back